Decreased recognition of paraneoplastic pemphigus in patients previously treated with anti-CD 20 monoclonal antibodies

Br J Dermatol. 2019 May;180(5):1238-1239. doi: 10.1111/bjd.17577. Epub 2019 Jan 15.

Authors

S G Kwatra¹, E Boozalis¹, H Pasieka², G J Anhalt¹

Affiliations

¹ Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.
² Department of Internal Medicine and Dermatology, Georgetown University, Washington, DC, U.S.A.

PMID: 30648258
DOI: 10.1111/bjd.17577

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antigens, CD20 / immunology
Antigens, CD20 / metabolism
Autoantibodies / immunology
Autoantibodies / metabolism
B-Lymphocytes / drug effects*
B-Lymphocytes / immunology
B-Lymphocytes / metabolism
Diagnostic Errors
Humans
Incidence
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell / etiology
Lymphoma, Non-Hodgkin / drug therapy
Lymphoma, Non-Hodgkin / etiology
Male
Middle Aged
Paraneoplastic Syndromes / diagnosis
Paraneoplastic Syndromes / epidemiology*
Paraneoplastic Syndromes / immunology
Pemphigus / diagnosis
Pemphigus / epidemiology*
Pemphigus / immunology
Rituximab / pharmacology*
Rituximab / therapeutic use
Skin / drug effects
Skin / immunology
Stevens-Johnson Syndrome / diagnosis
Stevens-Johnson Syndrome / immunology
T-Lymphocytes / immunology
Undiagnosed Diseases / diagnosis
Undiagnosed Diseases / epidemiology*

Substances

Antigens, CD20
Autoantibodies
Rituximab